Privia Health Group, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan Langston from TD Cowen maintained a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Langston has given his Buy rating due to a combination of factors including Privia Health Group’s impressive financial performance and strategic growth initiatives. The company exceeded expectations in the second quarter of 2025 with a 12% higher adjusted EBITDA than consensus estimates, driven by strong revenue and Shared Savings performance. Furthermore, Privia Health Group has raised its full-year 2025 guidance metrics, reflecting confidence in their expansion strategy, particularly with their entry into Arizona through the IMS transaction.
Additionally, Privia Health Group continues to excel in the dynamic healthcare services market with its diverse Value-Based Care contracts and a consistent revenue stream. The management’s optimistic outlook for 2025, with increased guidance for key metrics, underscores their effective risk management and operational execution. The company’s robust expansion pipeline and strategic acquisitions, coupled with favorable regulatory developments, further solidify its position as a top pick in the sector. Consequently, the price target remains at $30, based on a 2026 estimated EV/EBITDA target of 27x.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRVA in relation to earlier this year.